title: Osmic acid revisited: factors that predict a favourable response.
abstract: OBJECTIVE
  Chemical synovectomy with osmic acid has been used for many years in the treatment of chronic synovitis that is unresponsive to systemic treatment and intra-articular corticosteroid. Our aims were to compare the safety and the efficacy of this procedure with that of alternative treatment modalities, and to identify any factors that may predict the response to treatment.
  
  
  METHODS
  A retrospective review of 103 osmic acid injections was performed in 65 patients with chronic knee synovitis, between 1992 and 1998. After a clinical review 6 weeks after injection, the length of remission was determined by telephone survey. Thirty-six months of follow-up was available for 96 injections, with a minimum of 12 months for the remainder. Remission was defined as complete absence of pain and swelling.
  
  
  RESULTS
  Sixty-nine (67.0%) knee joints remained completely free of pain and swelling at 6 months, falling to 52 (50.5%) at 12 months, 32 (31.1%) at 24 months, and 19 (18.4%) at 36 months. Knees with mild radiological changes experienced significantly better results compared with those with moderate or severe changes (P=0.006 and 0.046 respectively). In patients undergoing bilateral injections, there was a correlation between the duration of remission achieved for each of the two knees (r=0.83, P < 0.01). A correlation was also observed between the responses obtained after first and repeated synovectomies of the same knee (r=0.62, P < 0.05). Eighty-six per cent of injections were uncomplicated. Side-effects included pain, which followed 13 injections (12.4%), and two skin burns.
  
  
  CONCLUSIONS
  Long-term complete remission was achieved in 18.4% of knees. This treatment may be best reserved for joints with less severe radiological changes. The response to a first osmic acid injection has a strong predictive value when considering further treatment of the same or the contralateral joint.
authors.affiliation: Department of Rheumatology, Northwick Park Hospital, London, UK. r.bessant@ucl.ac.uk
authors.forename: R
authors.initials: R
authors.lastname: Bessant
authors.forename: A
authors.initials: A
authors.lastname: Steuer
authors.forename: S
authors.initials: S
authors.lastname: Rigby
authors.forename: M
authors.initials: M
authors.lastname: Gumpel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007270:Injections, Intra-Articular; D007719:Knee Joint / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009993:Osmium Tetroxide / Q000009:adverse effects; D011379:Prognosis; D011859:Radiography; D012074:Remission Induction; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013585:Synovitis / Q000000981:diagnostic imaging / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D009993:Osmium Tetroxide